Charlotte Carton

Charlotte Carton

Auto-generated profile, based on publicly available information

Charlotte Carton

Laboratory for Neurofibromatosis Research, Department of Human Genetics, University of Leuven, KU Leuven, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in eClinicalMedicine
Verified
Journal Article
Open access
CCCharlotte Carton
Charlotte Carton
DED. Gareth Evans
D. Gareth Evans
IBIgnacio Blanco
Ignacio Blanco
RFReinhard E. Friedrich
Reinhard E. Friedrich
RFRosalie E. Ferner
Rosalie E. Ferner
AWAnja Wagner
Anja Wagner
Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder, predisposing development of benign and malignant tumours. Given the oncogenic potential, long-term surveillance is important in patients with NF1. Proposals for NF1 care and its specific manifestations have been developed, but lack integration within routine care. This guideline aims to assimilate available information on NF1 associated tumours (based on evidence and/or expert opinion) to assist healthcare professionals in undertaking tumour surveillance of NF1 individuals. By comprehensive literature review, performed March 18th 2020, guidelines were developed by a NF1 expert group and patient representatives, conversant with clinical care of the wide NF1 disease spectrum. We used a modified Delphi procedure to overcome issues of variability in recommendations for specific (national) health care settings, and to deal with recommendations based on indirect (scarce) evidence. We defined proposals for personalised and targeted tumour management in NF1, ensuring appropriate care for those in need, whilst reducing unnecessary intervention. We also incorporated the tumour-related psychosocial and quality of life impact of NF1. The guideline reflects the current care for NF1 in Europe. They are not meant to be prescriptive and may be adjusted to local available resources at the treating centre, both within and outside EU countries. This guideline has been supported by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS). ERN GENTURIS is funded by the European Union. DGE is supported by the Manchester NIHRBiomedical Research Centre (IS-BRC-1215-20007).

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
AVA. Vanhaecke
A. Vanhaecke
VSVanessa Smith
Vanessa Smith
SPSabrina Paolino
Sabrina Paolino
KMK. Melsens
K. Melsens
YPY. Piette
Y. Piette
MCMaurizio Cutolo
Maurizio Cutolo
Background At this very moment, no systematic review evaluating the role of nailfold videocapillaroscopy (NVC) with standardised definitions, in interstitial lung disease (ILD) has been published. Objectives To systematically identify and review all available literature evaluating the role of NVCin ILD in SSc, according to the definitions of the EULAR study group on microcirculation in Rheumatic diseases. Methods A systematic literature search was performed in Pubmed, EMBASE and Web of Science. All retrieved articles were screened on title, abstract and full-text level. Reference lists and google scholar were additionally searched. Original research papers that documented an association between NVC and ILD in SSc were included. Subsequently, NVC parameters were subdivided in quantitative (density, dimension, morphology and haemorrhages), semi-quantitative (NVC score) and qualitative assessment (presence, severity and worsening of scleroderma pattern). Results The systematic search identified 299 unique search results, of which 145 references were withheld after title screening. Abstract screening resulted in 39 references, only 16 were eligible for full-text review. Finally, 16 references were included in the final analysis after full-text screening (n=13) and bibliographic and google scholar search (n=3) (see table 1). Regarding cross-sectional studies, density has been evaluated in 5 studies and has been unequivocally associated with DLCO/AV, DLCO, FVC and inversely with GGO. Dimension has been evaluated in 4 studies, with no unequivocal results. Morphology has been evaluated in 1 study and has been unequivocally associated with HC on HRCT. Haemorrhages have not been evaluated. NVC score has been evaluated in 2 studies and has been unequivocally associated with GGO on HRCT and total lung score. Presence of scleroderma pattern has been evaluated in 3 studies and has been unequivocally associated with reduction of DLCO and severe lung involvement. Severity of scleroderma pattern has been evaluated in 4 studies and has been unequivocally associated with reduction of DLCO and FVC, ILD on chest X-ray and lung involvement. Regarding longitudinal studies, density has been evaluated in 2 studies and has been unequivocally associated with reduction of DLCO. Dimension, morphology and haemorrhages have all been evaluated in 1 study, with no association. NVC score has not been evaluated. Presence of scleroderma pattern has been evaluated in 2 studies and has been unequivocally associated with reduction of DLCO, ILD on HRCT and future severe lung involvement. Worsening of scleroderma pattern has been evaluated in 1 study and has been unequivocally associated with future lung involvement. Conclusions This systematic literature review, on behalf of the EULAR study group on microcirculation in Rheumatic diseases, is the first to investigate unequivocal associations between ILD and capillaroscopic alterations in a standardised way. Unequivocal associations were found in cross-sectional studies between density, morphology, NVC score, presence and severity of scleroderma pattern and in longitudinal studies between density, presence and worsening of scleroderma pattern and ILD-defining parameters in SSc patients. References [1] De Santis M. Auto Immun Highlights.2016; [2] Sato LT. Acta Reumatol Port.2009; [3] Pizzorni C. J Rheum.2017; [4] Castellvi I. J Rehum.2015; [5] Hissaria P. Int J Med.2011; [6] Avouac J. Sermin Arthritis Rheum.2017; [7] Bredemeier M. J Rheum.2004; [8] Indiveri F. Ann Ital Med Int. 1999; [9] Medsger TA. Clin Exp Rheum.2003; [10] Fichel F. Dermatology.2014; [11] Smith V. Rheumatology.2012; [12] Ghizzoni C. Microvasc Res.2015; [13] Ingegnoli F. Microvasc Res.2013; [14] Jehangir M. Int J Res Med Sci.2015; [15] Markusse IM. Rheumatology2017; [16] Caramaschi P. Rheumatology.2007; [17] Claverie ML. Clin Rheumatol. 2013 Disclosure of Interest None declared